A record of what Axis Securities Analysis said publicly, with the source. Not advice.
“Recommends buying Natco Pharma in the range of ₹1,285-1,235, targeting ₹1,616 and potentially ₹1,785, expecting a decent upside of 18%-46% in 2025 based on technical and fundamental strength.”
Axis Securities Analysis’s track record (trackable calls only): 155 graded calls · 95% CI 34–49%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry zone: ₹1,235–₹1,285. The call starts at the first close that comes into it.
Target ₹1,616, as stated.
Window: 12 months, the default when no time frame is stated.
Neither the target ₹1,616 was reached on a close by the end of the window. Miss.
The grader’s working: R3 TRADE_SETUP: entered ₹1277.8 on 2025-01-09 (stated entry ₹1235–1285 zone, ZONE entry, filled); neither target nor stop reached by window end 2026-01-01. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.